Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

Carol Pollock; Bergur Stefánsson; Daniel Reyner; Peter Rossing; C David Sjöström; David C Wheeler; Anna Maria Langkilde; Hiddo J L Heerspink

doi:10.1016/s2213-8587(19)30086-5

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(19)30086-5 ◽

2019 ◽

Vol 7 (6) ◽

pp. 429-441 ◽

Cited By ~ 45

Author(s):

Carol Pollock ◽

Bergur Stefánsson ◽

Daniel Reyner ◽

Peter Rossing ◽

C David Sjöström ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Glycaemic Control ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Lowering Effect

Download Full-text

Faculty Opinions recommendation of Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735542506.793559665 ◽

2019 ◽

Author(s):

Carmine Zoccali ◽

Davide Bolignano

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Glycaemic Control ◽

Controlled Trial ◽

Double Blind ◽

Double Blind Placebo ◽

Lowering Effect

Download Full-text

Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial

The Lancet Diabetes & Endocrinology ◽

10.1016/s2213-8587(13)70208-0 ◽

2014 ◽

Vol 2 (5) ◽

pp. 369-384 ◽

Cited By ~ 308

Author(s):

Anthony H Barnett ◽

Ambrish Mithal ◽

Jenny Manassie ◽

Russell Jones ◽

Henning Rattunde ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Faculty Opinions recommendation of Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718462631.793518344 ◽

2016 ◽

Author(s):

Sydney Tang ◽

Gary Chan

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

The effects of vitamin D2 or D3supplementation on glycaemic control and related metabolic parameters in people at risk of type 2 diabetes: protocol of a randomised double-blind placebo-controlled trial

BMC Public Health ◽

10.1186/1471-2458-13-999 ◽

2013 ◽

Vol 13 (1) ◽

Cited By ~ 3

Author(s):

Ravi K Menon ◽

Anna P Rickard ◽

Nasima Mannan ◽

Peter M Timms ◽

Stephen J Sharp ◽

...

Keyword(s):

Type 2 Diabetes ◽

At Risk ◽

Glycaemic Control ◽

Controlled Trial ◽

Metabolic Parameters ◽

Vitamin D2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12047 ◽

2013 ◽

Vol 15 (5) ◽

pp. 432-440 ◽

Cited By ~ 90

Author(s):

K. Kaku ◽

S. Inoue ◽

O. Matsuoka ◽

A. Kiyosue ◽

H. Azuma ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Type 2 Diabetes Mellitus ◽

Glycaemic Control ◽

Controlled Trial ◽

Japanese Patients ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Effects of vitamin D2 or D3 supplementation on glycaemic control and cardiometabolic risk among people at risk of type 2 diabetes: results of a randomized double-blind placebo-controlled trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12625 ◽

2016 ◽

Vol 18 (4) ◽

pp. 392-400 ◽

Cited By ~ 43

Author(s):

N. G. Forouhi ◽

R. K. Menon ◽

S. J. Sharp ◽

N. Mannan ◽

P. M. Timms ◽

...

Keyword(s):

Type 2 Diabetes ◽

At Risk ◽

Glycaemic Control ◽

Cardiometabolic Risk ◽

Controlled Trial ◽

Vitamin D2 ◽

Double Blind ◽

Double Blind Placebo

Download Full-text

Combined SGLT ‐2 and ACE inhibition upregulates the renin‐angiotensin system in chronic kidney disease with type 2 diabetes: Results of a randomized, double‐blind, placebo‐controlled exploratory trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14639 ◽

2022 ◽

Author(s):

Marlies Antlanger ◽

Oliver Domenig ◽

Christopher C Kaltenecker ◽

Johannes J Kovarik ◽

Vincent Rathkolb ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Renin Angiotensin System ◽

Ace Inhibition ◽

Double Blind ◽

Angiotensin System ◽

Double Blind Placebo ◽

Exploratory Trial

Download Full-text

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

The Lancet ◽

10.1016/s0140-6736(19)30772-x ◽

2019 ◽

Vol 393 (10184) ◽

pp. 1937-1947 ◽

Cited By ~ 97

Author(s):

Hiddo J L Heerspink ◽

Hans-Henrik Parving ◽

Dennis L Andress ◽

George Bakris ◽

Ricardo Correa-Rotter ◽

...

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Double Blind

Download Full-text

Faculty Opinions recommendation of Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735578274.793564592 ◽

2019 ◽

Author(s):

Luis Ruilope

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Double Blind

Download Full-text

Faculty Opinions recommendation of Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.735578274.793559664 ◽

2019 ◽

Author(s):

Carmine Zoccali ◽

Davide Bolignano

Keyword(s):

Type 2 Diabetes ◽

Chronic Kidney Disease ◽

Kidney Disease ◽

Controlled Trial ◽

Double Blind

Download Full-text